芒果视频下载

成立于1998年，知名阿膠品牌，以藥業/酒業為主導，集研發/生產/經營/投資/管理于一體的綜合性集團公司，產品涵蓋了中西藥制劑/生物制藥/原料藥/保健食品等品類

1998年成立的輔仁藥業集團，是一家以藥業、酒業為主導，集研發、生產、經營、投資、管理于一體的綜合性集團公司。集團(tuan)(tuan)囊括河南(nan)輔(fu)仁(ren)堂制(zhi)(zhi)藥(yao)(yao)有(you)(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、河南(nan)輔(fu)仁(ren)懷慶堂制(zhi)(zhi)藥(yao)(yao)有(you)(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、開封制(zhi)(zhi)藥(yao)(yao)（集團(tuan)(tuan)）有(you)(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、開封豫港制(zhi)(zhi)藥(yao)(yao)有(you)(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、開藥(yao)(yao)集團(tuan)(tuan)（開魯）制(zhi)(zhi)藥(yao)(yao)有(you)(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、河南(nan)同(tong)源(yuan)制(zhi)(zhi)藥(yao)(yao)有(you)(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、輔(fu)仁(ren)醫(yi)藥(yao)(yao)科技開發有(you)(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、輔(fu)仁(ren)藥(yao)(yao)業(ye)集團(tuan)(tuan)醫(yi)藥(yao)(yao)有(you)(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、輔(fu)仁(ren)藥(yao)(yao)業(ye)集團(tuan)(tuan)熙德隆腫瘤(liu)藥(yao)(yao)品有(you)(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、北京遠(yuan)策藥(yao)(yao)業(ye)有(you)(you)(you)(you)限(xian)(xian)責(ze)任公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、北京輔(fu)仁(ren)瑞輝生(sheng)物醫(yi)藥(yao)(yao)研究(jiu)院、上海輔(fu)仁(ren)醫(yi)藥(yao)(yao)研發有(you)(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、鄭州(zhou)遠(yuan)策生(sheng)物制(zhi)(zhi)藥(yao)(yao)有(you)(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、河南(nan)省宋河酒業(ye)股份(fen)有(you)(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)及上市公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)輔(fu)仁(ren)藥(yao)(yao)業(ye)集團(tuan)(tuan)制(zhi)(zhi)藥(yao)(yao)股份(fen)有(you)(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)等多(duo)家全資(zi)、控股子公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)。

集(ji)團(tuan)產(chan)品涵(han)蓋了中西藥(yao)(yao)制(zhi)(zhi)(zhi)劑、生物制(zhi)(zhi)(zhi)藥(yao)(yao)、原料藥(yao)(yao)、保健食品等(deng)多個(ge)(ge)門類。2006年，隨著河南輔(fu)仁(ren)(ren)(ren)堂制(zhi)(zhi)(zhi)藥(yao)(yao)有限公司(si)(si)成(cheng)功實(shi)現上市，資本的(de)(de)力量(liang)不僅把輔(fu)仁(ren)(ren)(ren)推向一個(ge)(ge)飛速發展時(shi)期，其行業(ye)地位亦逐步提(ti)升(sheng)。2017年12月(yue)29日，輔(fu)仁(ren)(ren)(ren)藥(yao)(yao)業(ye)重(zhong)大(da)資產(chan)重(zhong)組成(cheng)功，把集(ji)團(tuan)優質(zhi)資產(chan)——開封制(zhi)(zhi)(zhi)藥(yao)(yao)（集(ji)團(tuan)）有限公司(si)(si)置(zhi)入輔(fu)仁(ren)(ren)(ren)藥(yao)(yao)業(ye)，使(shi)輔(fu)仁(ren)(ren)(ren)藥(yao)(yao)業(ye)跨入一個(ge)(ge)新(xin)的(de)(de)發展階段。

“品(pin)(pin)(pin)種(zhong)為(wei)核心，并購為(wei)主(zhu)線”的早期發(fa)展(zhan)戰(zhan)略讓(rang)輔(fu)仁(ren)(ren)藥(yao)業集(ji)團的產能和產品(pin)(pin)(pin)線在很短時間內飛速發(fa)展(zhan)。迄今(jin)，輔(fu)仁(ren)(ren)藥(yao)業集(ji)團已擁有(you)水(shui)針劑(ji)(ji)、凍干粉針劑(ji)(ji)、口服(fu)固體(ti)制劑(ji)(ji)等20多(duo)個(ge)(ge)(ge)(ge)(ge)(ge)劑(ji)(ji)型(xing)，1000余個(ge)(ge)(ge)(ge)(ge)(ge)品(pin)(pin)(pin)種(zhong)；制劑(ji)(ji)綜合產能位居全(quan)國制藥(yao)行(xing)業前(qian)茅。2017新版醫保目錄輔(fu)仁(ren)(ren)藥(yao)業集(ji)團共(gong)入(ru)(ru)選578個(ge)(ge)(ge)(ge)(ge)(ge)品(pin)(pin)(pin)種(zhong)，較2009版目錄增加品(pin)(pin)(pin)種(zhong)165個(ge)(ge)(ge)(ge)(ge)(ge)，增幅(fu)39.95%，其中(zhong)甲類入(ru)(ru)選364個(ge)(ge)(ge)(ge)(ge)(ge)，增幅(fu)42.754%，乙類入(ru)(ru)選214個(ge)(ge)(ge)(ge)(ge)(ge)，增幅(fu)35.44%。在國家衛(wei)健委正式(shi)發(fa)布《國家基本藥(yao)物目錄（2018年版）》中(zhong)，輔(fu)仁(ren)(ren)藥(yao)業集(ji)團共(gong)有(you)阿(a)莫(mo)西林克拉維酸鉀干混懸劑(ji)(ji)、奧美拉唑腸溶(rong)膠囊、注射用重(zhong)組(zu)人干擾素α2b等262個(ge)(ge)(ge)(ge)(ge)(ge)品(pin)(pin)(pin)規榜上有(you)名，較2012版目錄增加75個(ge)(ge)(ge)(ge)(ge)(ge)，增幅(fu)40.11%，成(cheng)為(wei)全(quan)國入(ru)(ru)選品(pin)(pin)(pin)種(zhong)較多(duo)的制藥(yao)企(qi)業之一。

輔仁藥業(ye)集團一直遵(zun)循“濟世藥為(wei)(wei)輔、惠民(min)志在仁”的(de)(de)企業(ye)理(li)念，始終貫(guan)徹“產量讓(rang)位于質量、成(cheng)本讓(rang)位于質量”的(de)(de)質量管理(li)方針(zhen)，本著(zhu)“和而不同、化繁為(wei)(wei)簡、務實創新、濟世惠民(min)”的(de)(de)企業(ye)價值觀(guan)，把“做一家實體型(xing)、科技型(xing)、國際型(xing)企業(ye)”作為(wei)(wei)自己的(de)(de)企業(ye)定(ding)位，兼(jian)容并蓄，尊重規律，踐行規則。

在(zai)(zai)企業(ye)并購的同時(shi)，輔仁藥業(ye)集團(tuan)投入巨(ju)資加強企業(ye)創新(xin)(xin)平(ping)(ping)臺建設，戰略性布局(ju)鄭州技術研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)和(he)國際化合作(zuo)及產(chan)業(ye)化服務(wu)平(ping)(ping)臺、北京創新(xin)(xin)研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)平(ping)(ping)臺、上(shang)海醫(yi)藥研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)創新(xin)(xin)國際合作(zuo)平(ping)(ping)臺、美國新(xin)(xin)澤西(xi)、費城(cheng)研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)平(ping)(ping)臺四大(da)研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)創新(xin)(xin)平(ping)(ping)臺，以及中醫(yi)藥大(da)數據及人工智能中醫(yi)研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)平(ping)(ping)臺，更將在(zai)(zai)小(xiao)分(fen)子(zi)化學藥、大(da)分(fen)子(zi)生物藥研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)和(he)中醫(yi)藥傳承(cheng)創新(xin)(xin)方(fang)向(xiang)同時(shi)發(fa)(fa)力(li)，開辟以研(yan)(yan)(yan)(yan)(yan)(yan)發(fa)(fa)驅動創新(xin)(xin)的發(fa)(fa)展(zhan)新(xin)(xin)路徑。

目前，輔仁藥業(ye)集團支持創新研發面(mian)積達11.3萬平方米，研發創新隊伍近1500人。同時(shi)，秉(bing)承“中國市場、輔仁平臺、全(quan)球資源”的(de)發展策略(lve)，輔仁藥業(ye)集團實現了從“百(bai)姓藥、輔仁造(zao)”到“創新藥、輔仁造(zao)”的(de)可(ke)持續發展跨越(yue)，為客戶(hu)及整個社會創造(zao)價值，健(jian)康(kang)中國，服務世界(jie)。